A5090561717- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Viral-associated cancers and disorders
- CNS Lymphoma Diagnosis and Treatment
- Cutaneous lymphoproliferative disorders research
- T-cell and Retrovirus Studies
- Lung Cancer Treatments and Mutations
- CAR-T cell therapy research
- Sarcoma Diagnosis and Treatment
- Immunodeficiency and Autoimmune Disorders
- Histiocytic Disorders and Treatments
- Medical Imaging Techniques and Applications
- Biosimilars and Bioanalytical Methods
- Radiomics and Machine Learning in Medical Imaging
- Cardiac tumors and thrombi
- Vascular Tumors and Angiosarcomas
- Neutropenia and Cancer Infections
- Acute Lymphoblastic Leukemia research
- Monoclonal and Polyclonal Antibodies Research
- Chronic Myeloid Leukemia Treatments
- Cancer Immunotherapy and Biomarkers
- Fungal Infections and Studies
- Genital Health and Disease
- Immune Cell Function and Interaction
- Gut microbiota and health
University of Bologna
2016-2025
Istituto di Ematologia di Bologna
2010-2025
Policlinico S.Orsola-Malpighi
2012-2025
Azienda USL di Bologna
2020-2024
Istituti di Ricovero e Cura a Carattere Scientifico
2021-2022
Hospital Universitario de Getafe
2020
Istituto Oncologico Romagnolo
2009-2018
John Radcliffe Hospital
2015
Presidio Ospedaliero
2010
Novamont (Italy)
2010
BRAF V600E is the genetic lesion underlying hairy-cell leukemia. We assessed safety and activity of oral inhibitor vemurafenib in patients with leukemia that had relapsed after treatment a purine analogue or who disease was refractory to analogues.
Purpose In lymphoma, [ 18 F]fluorodeoxyglucose positron emission tomography (FDG-PET) is routinely used for initial staging, early evaluation of treatment response, and identification disease relapse. However, there are no prospective studies investigating the value serial FDG-PET over time in patients complete remission. Patients Methods All with lymphoma who achieved first remission were prospectively enrolled onto study scheduled scans at 6, 12, 18, 24 months; further then carried out on...
Purpose The clinical impact of positron emission tomography (PET) evaluation performed early during first-line therapy in patients with advanced-stage Hodgkin lymphoma, terms providing a rationale to shift who respond poorly onto more intensive regimen (PET response-adapted therapy), remains be confirmed. Patients and Methods phase II part the multicenter HD0801 study involved 519 de novo lymphoma received an initial treatment doxorubicin, bleomycin, vinblastine, dacarbazine (ABVD) underwent...
Splenic marginal zone B-cell lymphoma (SMZL) is a heterogeneous clinico-biological entity. The clinical course variable, multiple genes are mutated with no unifying mechanism, and essential regulatory pathways surrounding microenvironments diverse. We sought to clarify the heterogeneity of SMZL by resolving different subgroups their underlying genomic abnormalities, pathway signatures, microenvironment compositions uncover biomarkers therapeutic vulnerabilities. studied 303 spleen samples...
Peripheral T-cell lymphoma not otherwise specified represents a diagnostic category comprising clinically, histologically, and molecularly heterogeneous neoplasms that are poorly understood. The genetic landscape of peripheral remains largely undefined, only few sequencing studies having been conducted so far. In order to improve our understanding the genetics this neoplasm, we performed whole exome along with RNA-sequencing in discovery set 21 cases. According results mutations previously...
Abstract Purpose: This study aimed to evaluate the efficacy and safety of treatment with 90Y-ibritumomab tiuxetan following a short-course rituximab cyclophosphamide-adriamycin-vincristine-prednisone (R-CHOP) in high-risk elderly patients previously untreated diffuse large B-cell lymphoma (DLBCL). Experimental Design: From December 2006 October 2008, 55 (age ≥60 years) DLBCL were treated seven Italian institutions chemotherapy consisting four cycles R-CHOP21 followed by 6 10 weeks later....
Abstract BACKGROUND: The use of 18 F‐fluorodeoxyglucose positron‐emission tomography (PET) scan has increased considerably in the clinical management non‐Hodgkin lymphoma patients, and its role as a prognostic factor during chemotherapy been established recently. METHODS: Between May 2003 2009, 91 newly diagnosed patients with primary mediastinal large B‐cell (PMLBCL) diffuse (DLBCL) were treated 12 weekly cycles rituximab‐MACOP‐B (n = PMLBCL), 6 rituximab‐CHOP21 65 DLBCL, aged < 60 years...
BACKGROUND: Historically, the first treatment choices for hairy cell leukemia (HCL) were splenectomy and alpha-interferon. Recently, purine analogues (pentostatin cladribine) changed radically modality, inducing complete durable responses in majority of patients. METHODS: The authors analyzed outcome different lines therapy 121 HCL patients followed their institute from 1986 to 2008, with a median follow-up 105 months. Patients divided into subgroups according number treatments; Group A...
Abstract Effective salvage options inducing high complete metabolic response (CMR) rates without significant toxicity are needed for Hodgkin lymphoma (HL) patients failing induction treatment and who candidate to autologous stem cell transplantation (ASCT). Brentuximab vedotin (BV) bendamustine active monotherapies in the relapsed/refractory setting their combination (the BBV regimen) possibly enhances activity. This single-arm multicenter phase 2 study investigated efficacy safety of as...
Large B-cell lymphomas (LBCL) are the most common types of non-Hodgkin lymphoma. Although outcomes have improved thanks to introduction rituximab-based chemoimmunotherapy, certain LBCL still represents a challenge because initial resistance therapy or recurrent relapses. Axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) second-generation autologous CD19-targeted chimeric antigen receptor (CAR) T-cell therapies approved for patients with relapsed/refractory (R/R) LBCL, based...
Abstract Regarding primary mediastinal large B‐cell lymphoma (PMLBCL), there are several controversial topics that warrant further investigation: the superiority of third‐generation regimens, impact rituximab, use involved field radiotherapy (RT) and assessment clinical response by positron emission tomography (PET). We report our experience on 74 PMLBCL patients treated with a combination chemotherapy regimen (MACOP‐B) rituximab: an observational retrospective single‐centre study was...
Hairy cell leukemia (HCL) is a rare lymphoproliferative disease with an excellent prognosis after treatment cladribine (2CDA), although relapse may occur during follow-up. The aim of the study to review efficacy, safety, long-term remission rate, and overall survival (OS) in those patients who received 2CDA as first-line treatment. We retrospectively reviewed data HCL treated between March 1991 May 2019 at 18 Italian Hematological centers: 513 were evaluable for purpose. median age was 54...